Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater JL; Clinical Trials Group of the National Cancer Institute of Canada. Bezjak A, et al. Among authors: smith c. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):719-28. doi: 10.1016/s0360-3016(02)02989-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377323 Clinical Trial.
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H, Devore RF 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH. Choy H, et al. Among authors: smith c. Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):931-7. doi: 10.1016/s0360-3016(00)00420-x. Int J Radiat Oncol Biol Phys. 2000. PMID: 10863062 Clinical Trial.
Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M 3rd, Andras EJ. Werner-Wasik M, et al. Among authors: smith c. Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):327-31. doi: 10.1016/s0360-3016(99)00031-0. Int J Radiat Oncol Biol Phys. 1999. PMID: 10760427
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Movsas B, et al. Among authors: smith c. J Clin Oncol. 2005 Apr 1;23(10):2145-54. doi: 10.1200/JCO.2005.07.167. J Clin Oncol. 2005. PMID: 15800308 Clinical Trial.
Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy.
Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, Brade A. Bebb G, et al. Among authors: smith c. Cancer Chemother Pharmacol. 2011 Apr;67(4):837-45. doi: 10.1007/s00280-010-1379-9. Epub 2010 Jun 20. Cancer Chemother Pharmacol. 2011. PMID: 20563810 Clinical Trial.
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ. Choy H, et al. Among authors: smith c. J Clin Oncol. 2005 Sep 1;23(25):5918-28. doi: 10.1200/JCO.2005.08.011. J Clin Oncol. 2005. PMID: 16135463 Clinical Trial.
21,638 results
You have reached the last available page of results. Please see the User Guide for more information.